In preclinical tumor models, IMANs enhanced effector cell recruitment, resulting in increased tumor cell death. Additionally, they synergised with CAR-T cells to enhance tumor clearance in models of ...

They're exploring its use for groundbreaking treatments for cancer and autoimmune disease, as well as for gene-editing ...

Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in adeno-associated virus (AAV) gene therapy, today announced a major expansion of its artificial intelligence and machine learning ...

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

Q3 2025 Earnings Call Transcript October 29, 2025 BridgeBio Pharma, Inc. misses on earnings expectations. Reported EPS is $-0 ...

December 6 - 9, 2025. "The data we’re presenting at this year’s ASH meeting reflect the strong momentum of our in vivo programs for sickle cell disease (SCD) and T-cell engineering,” said Michael ...

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO® (faricimab injection) Pre-Filled Syringe (PFS) is now publicly funded though the Ontario Drug Benefit Program.1 ...

In addition to the new NSF grant, the company has raised a $1.9M pre-seed round from 2048.vc, The Venture Collective (TVC), Pioneer Fund, and Portland Seed Fund, and secured a $275k Phase I NSF SBIR ...

Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated platforms at the 2025 Festival of Biologics in Basel. Over 2,000 biotech experts from ...

Net Loss -- Net loss was $13.6 million for the third quarter of 2025, compared to $16.4 million in Q3 2024. Ending Cash, Cash ...

Manhattan Associates, Inc. ( NASDAQ: MANH) Q3 2025 Earnings Call October 21, 2025 4:30 PM EDT ...

New data provide key mechanistic insights into how TG4050 induces and sustains potent, CD8+ T cell responses in operable HNSCC[*] ...